ABSTRACT
Deep brain stimulation targeting the posterior hypothalamus (pHyp-DBS) is being investigated as treatment for refractory aggressive behaviour, but its mechanisms of action remain elusive. We conducted an integrated imaging analysis of a large multi-centre dataset, incorporating volume of activated tissue modeling, probabilistic mapping, normative connectomics, and atlas-derived transcriptomics. 91% of the patients responded positively to treatment, with a more striking improvement recorded in the pediatric population. Probabilistic mapping revealed an optimized surgical target within the posterior-inferior-lateral posterior hypothalamic area and normative connectomic analyses identified fiber tracts and interconnected brain areas associated with sensorimotor function, emotional regulation, and monoamine production. Functional connectivity between the target, periaqueductal gray and the amygdala – together with patient age – was highly predictive of treatment outcome. Finally, transcriptomic analysis showed that genes involved in mechanisms of aggressive behaviour, neuronal communication, plasticity and neuroinflammation may underlie this functional network.
SIGNIFICANCE STATEMENT This study investigated the brain mechanisms associated with symptom improvement following deep brain stimulation of the posterior hypothalamus for severe and refractory aggressive behavior. Conducting an integrated imaging analysis of a large international multi-center dataset of patients treated with hypothalamic deep brain stimulation, we were able to show for the first time that treatment is highly efficacious across various patients with an average improvement greater than 70%. Leveraging this unique dataset allowed us to demonstrate that some patient characteristics are important for treatment success, describe the optimal target zone for maximal benefit, that engagement of distinct fiber tracts and networks within the emotional neurocircuitry are key for positive outcome, and - using imaging transcriptomics - elucidate some potential molecular underpinnings. The provided optimal stimulation site allows for direct clinical application.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funds from the Harquail Center for Neuromodulation, Canadian Institutes of Health Research (CIHR) Postdoctoral Fellowship #472484 (FVG), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) #13/20602-5 (FVG), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) #17/10466-8 (FVG), Canadian Institutes of Health Research (CIHR) Banting fellowship #471913 (JG), and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) #11/08575-7 (RCRM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study approval: Individual trials and cases were evaluated by the corresponding local ethics committee and written informed consent was obtained. Five international centers shared clinical data for this study. 1. Comite de Etica de la Investigacion of Hospital Universitario San Vicente Fundacion gave ethical approval for this work. 2. Comite de Etica de la Investigacion con Medicamentos of Hospital Universitario La Princesa gave ethical approval for this work. 3. Comite de Etica de los Estudios Clinicos of La Misericordia Clinica Internacional gave ethical approval for this work. 4. Comite Institucional de Etica of Universidad Autonoma de Bucaramanga gave ethical approval for this work. 5. Comite de Etica em Pesquisa of Sociedade Beneficente de Senhoras Hospital Sirio-Libanes gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict-of-interest statement: The authors have declared that no conflict of interest exists
Data Availability
All data produced in the present study are available upon reasonable request to the authors
